# Insulin Aspart (NovoLog)

> Rapid-acting mealtime insulin analog.

Source: https://peptides.cafe/peptide/insulin-aspart
Category: Insulin Analog · Endocrine
Tag: FDA-Approved · Diabetes

## Mechanism
Recombinant insulin analog with proline→aspartic acid at B28, reducing hexamer stability for rapid absorption and prandial glucose control.

## Research areas
- Prandial coverage
- CSII pump therapy
- Inpatient glycemic management

## Common research protocols
- Mealtime SC: Subcutaneous dose within 5–10 minutes of starting a meal.

## Study summaries
- "Aspart vs regular insulin postprandial control" — Diabetes Care (2000): Better postprandial glucose with similar overall safety.

## Considerations
- FDA-approved.
- Hypoglycemia is the principal risk.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.